Download PDF
Dialyse aktuell 2016; 20(05): 228-232
DOI: 10.1055/s-0042-108125
Nephrologie
© Georg Thieme Verlag Stuttgart · New York

Das hepatorenale Syndrom

Aktuelles zu Diagnose, Prävention und TherapieHepatorenal syndrome – Current issues regarding diagnostics, prevention and therapy
Dietrich Hasper
1   Klinik für Nephrologie und Internistische Intensivmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin (komm. Klinikdirektor: PD Dr. Andreas Kahl)
,
Achim Jörres
2   Medizinische Klinik I, Krankenhaus Köln-Merheim, Klinikum der Universität Witten/Herdecke, Köln (Chefarzt: Prof. Dr. Achim Jörres)
› Author Affiliations
Further Information

Publication History

Publication Date:
24 June 2016 (online)

Also available at
    Permissions and Reprints

Eine akute Nierenschädigung bei Patienten mit fortgeschrittener Lebererkrankung ist ein häufiges klinisches Problem. Die Prognose dieser Patienten ist erheblich eingeschränkt. Häufige Ursachen für eine Nierenfunktionsverschlechterung sind die prärenale Azotämie, die akute Tubulusnekrose oder das hepatorenale Syndrom. Die vom International Ascites Club 2015 publizierten neuen Empfehlungen zur Diagnose und Therapie der Nierenschädigung bei Patienten mit Leberzirrhose tragen dieser Heterogenität Rechnung. Zur Klassifizierung sollten nun die modifizierten KDIGO-Kriterien angewendet werden. Bei einem etablierten hepatorenalen Syndrom gilt die kombinierte Therapie mit Albumin und Terlipressin als Standard. Noradrenalin oder Midodrin sind mögliche Alternativen, falls Terlipressin nicht verfügbar ist. Die neuen Verfahren der Leberdialyse stellen eine hoffnungsvolle Option bei ausgewählten Patienten dar.

Acute kidney injury (AKI) in patients with chronic liver disease is a serious clinical problem associated with increased mortality. Different conditions such as simple prerenal azotemia, acute tubular necrosis or the hepatorenal syndrome may cause AKI in this setting. Therefore, the new recommendations published by the International Ascites Club 2015 introduced new algorithms for diagnosis and management of AKI. In summary, modified KDIGO criteria should be used to define AKI. In the case of an established hepatorenal syndrome, combined treatment with terlipressin/albumin has been proven effective in most of the published studies and should be regarded as the standard of care. Norepinephrine or midodrine are possible alternatives when terlipressin is not available. Extracorporeal liver support may be a promising option in selected patients.

Key words

acute kidney injury - hepatorenal syndrome - extracorporeal therapy
 

  • Literatur

  • 1 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis.. Hepatology 2008; 48: 2064-2077
    CrossrefGoogle Scholar
  • 2 van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction.. Kidney Int 2013; 84: 192-197
    CrossrefGoogle Scholar
  • 3 Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.. J Hepatol 2003; 38 (Suppl. 01) S69-S89
    Google Scholar
  • 4 Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.. World J Gastroenterol 2010; 16: 5139-5147
    CrossrefGoogle Scholar
  • 5 Belcher JM, Garcia-Tsao G, Sanyal AJ et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis.. Hepatology 2013; 57: 753-762
    CrossrefGoogle Scholar
  • 6 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group.. KDIGO Clinical Practice Guideline for Acute Kidney Injury.. Kidney Int 2012; (Suppl. 02) 1-138
    Google Scholar
  • 7 Angeli P, Gines P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.. J Hepatol 2015; 62: 968-974
    Google Scholar
  • 8 Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.. N Engl J Med 1999; 341: 403-409
    CrossrefGoogle Scholar
  • 9 Mazur JE, Cooper TB, Dasta JF. Terlipressin in hepatorenal syndrome.. Ann Pharmacother 2011; 45: 380-387
    CrossrefGoogle Scholar
  • 10 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.. Gastroenterology 2009; 137: 1179-1181
    Google Scholar
  • 11 Boyer TD, Sanyal AJ, Garcia-Tsao G et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics.. J Hepatol 2011; 55: 315-321
    CrossrefGoogle Scholar
  • 12 Cavallin M, Kamath PS, Merli M et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.. Hepatology 2015; 62: 567-574
    CrossrefGoogle Scholar
  • 13 Nassar JuniorAP, Farias AQ, D’ Albuquerque LA et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.. PLoS One 2014; 9: e107466
    CrossrefGoogle Scholar
  • 14 Wong F, Leung W, Al BM, Marquez M, Renner EL. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.. Liver Transpl 2015; 21: 300-307
    CrossrefGoogle Scholar
  • 15 Banares R, Nevens F, Larsen FS et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.. Hepatology 2013; 57: 1153-1162
    CrossrefGoogle Scholar
  • 16 Kribben A, Gerken G, Haag S et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.. Gastroenterology 2012; 142: 782-789
    CrossrefGoogle Scholar